Solution to Series 1
|
|
- Randolph Patrick
- 5 years ago
- Views:
Transcription
1 Dr A Hauser Analysis AS 2018 Solution to Series 1 1 a) We can compute the cumulative hazard function: We know that H(t) = t 0 h(u)du = t H(t) = log S(t) ( S(t) = exp t ) The following plot shows the survivor function for different : S(t) Survivor function = 2 = 1 = b) The density f(t) is given by f(t) = h(t) S(t) f(t) = 1 ( exp t ) t The cumulative distribution function F (t) is given by F (t) = 1 S(t) ( F (t) = 1 exp t ) c) f(t) t is the unconditional ( a priori ) probability that the nucleus decays in the small time interval [t, t + t] h(t) t, in contrast, is the probability that the nucleus decays in the interval [t, t + t], given that is has not decayed yet at time t 2 x i d i n i p i Ŝ(x i ) = P(X > x i ) se(ŝ(x i)) /8 7/8 = = /8 = /6 7/8 5/6 = 35/48 = = /5 35/48 3/5 = 7/16 = = /16 = /2 7/16 1/2 = 7/32 = =
2 Calculation in R: > x <- c(1, 1, 2, 4, 4, 4, 6, 9) > status <- c(1, 0, 1, 1, 1, 0, 1, 1) # 0 for censored > rsf <- survfit(surv(x, status) 1, conftype = "none") > summary(rsf) survfit(formula = Surv(x, status) ~ 1, conftype = "none") time nrisk nevent survival stderr NA R-Code for drawing the survival curve: > plot(rsf, xlab = "", ylab = "") 3 a) > library(survival) > turl <- " > ddiabetes <- readtable(turl, header = TRUE, sep = ",") > rsv <- survfit(surv(lzeit, tod) ~ 1, type = "kaplan-meier", ddiabetes) > plot(rsv, confint = FALSE, xlab = "", ylab = "") b) The groups (diabetic, non diabetic) have different KM-curves The people in the diabetes group, seem to die sooner > rsv2 <- survfit(surv(lzeit, tod) ~ diab, data = ddiabetes) > plot(rsv2, confint = FALSE, lty = 1:2, xlab = "", ylab = "") > legend(3000, 08, c("no diabetes", "diabetes"), lty = 1:2)
3 3 no diabetes diabetes c) > rsv0 <- summary(survfit(surv(lzeit, tod) ~ 1, subset = diab == 0, conftype = "n", data = ddiabetes), censor = TRUE) > ttime0 <- rsv0$time > tweight0 <- rsv0$nevent / rsv0$nrisk > tsmooth0 <- density(ttime0, kernel = "epanechnikov", weights = tweight0, n = 100, from = 0, to = 4000) > plot(tsmooth0$x, tsmooth0$y, type = "l", ylim = c(0, 00018), main = "Kernel estimators of hazards", xlab = "time", ylab = "Smoothed hazard") > rsv1 <- summary(survfit(surv(lzeit, tod) ~ 1, subset = diab == 1, conftype = "n", data = ddiabetes), censor = TRUE) > ttime1 <- rsv1$time > tweight1 <- rsv1$nevent / rsv1$nrisk > tsmooth1 <- density(ttime1, kernel = "epanechnikov", weights = tweight1, n = 100, from = 0, to = 4000) > lines(tsmooth1$x, tsmooth1$y, lty = 2) > legend(0, 00018, c('no diabetes', 'diabetes'), lty = 1:2) Kernel estimators of hazards Smoothed hazard no diabetes diabetes time In the graph above, we can see, that the risk for the people not having diabetes is estimated to be zero after approx 3000 days The ratio is then no longer meaningful > plot(tsmooth0$x, tsmooth1$y / tsmooth0$y, xlim = c(0, 2800), ylim = c(0, 10), type = "l", main = "Ratio of Smoothed Hazards", xlab = "time", ylab = "hazard ratio")
4 4 hazard ratio Ratio of Smoothed Hazards time d) The Log-Rank-Test (p-value=002) confirms the difference seen by eye: > survdiff(surv(lzeit, tod) ~ diab, data = ddiabetes) survdiff(formula = Surv(lzeit, tod) ~ diab, data = ddiabetes) diab= diab= Chisq= 55 on 1 degrees of freedom, p= 002 e) The plot shows a difference between diabetics and non diabetics Especially the young non diabetics have a considerable larger chance of survival compared to the other groups There is an interesting structure in the diabetics group The young diabetics have a clearly larger chance of survival in the first years after the operation Then their curves cross and the young diabetics die sooner Here we should check why this can be like that > rsv4b <- survfit(surv(lzeit, tod) ~ diab + strata(altgr), data = ddiabetes) > summary(rsv4b) > plot(rsv4b, lty = 1:4) > legend(3000, 095, legend = c("(0,0)", "(0,1)", "(1,0)", "(1,1)"), lty = 1:4) > text(3500, 099, "(diab,altgr)") (diab,altgr) (0,0) (0,1) (1,0) (1,1) When we stratify by gender, there is a group with only 3 observations, 2 of which censored (the censored observations are displayed by a + in the survival curves, this can be done with the argument marktime = TRUE in the plot()-function) This curve (female, non diabetics) is thus little meaningful
5 5 > rsv4a <- survfit(surv(lzeit, tod) ~ diab + strata(sex), data = ddiabetes) > summary(rsv4a) > plot(rsv4a, marktime = TRUE, lty = 1:4) > legend(3000, 09, legend = c("(0,0)", "(0,1)", "(1,0)", "(1,1)"), lty = 1:4) > text(3500, 095, "(diab,sex)") (diab,sex) (0,0) (0,1) (1,0) (1,1) f) Stratifying by age: > survdiff(surv(lzeit,tod) ~ diab + strata(altgr), data = ddiabetes) survdiff(formula = Surv(lzeit, tod) ~ diab + strata(altgr), data = ddiabetes) diab= diab= Chisq= 43 on 1 degrees of freedom, p= 004 The difference in survival between diabetics and non-diabetics is also significant, if we stratify by age Stratifying by gender: > survdiff(surv(lzeit,tod) ~ diab + strata(sex), data = ddiabetes) survdiff(formula = Surv(lzeit, tod) ~ diab + strata(sex), data = ddiabetes) diab= diab= Chisq= 49 on 1 degrees of freedom, p= 003 Again the difference is significant Age and sex seem to play a secondary role in this case This may be surprising and we will come back to this later 4 a) Type I censored data because animals enter the study at the same time and are observed for a fixed period of time b) Type II censored data because animals enter the study at the same time but are observed until a fixed portion of the subjects have died
dataset1 <- read.delim("c:\dca_example_dataset1.txt", header = TRUE, sep = "\t") attach(dataset1)
Worked examples of decision curve analysis using R A note about R versions The R script files to implement decision curve analysis were developed using R version 2.3.1, and were tested last using R version
More informationBiostatistics II
Biostatistics II 514-5509 Course Description: Modern multivariable statistical analysis based on the concept of generalized linear models. Includes linear, logistic, and Poisson regression, survival analysis,
More informationBackcalculating HIV incidence and predicting AIDS in Australia, Cambodia and Vietnam. Australia
Backcalculating HIV incidence and predicting AIDS in Australia, Cambodia and Vietnam The aim of today s practical is to give you some hands-on experience with a nonparametric method for backcalculating
More informationPackage prognosticroc
Type Package Package prognosticroc February 20, 2015 Title Prognostic ROC curves for evaluating the predictive capacity of a binary test Version 0.7 Date 2013-11-27 Author Y. Foucher
More informationSupplementary Online Content
Supplementary Online Content Zusterzeel R, Selzman KA, Sanders WE, et al. Cardiac resynchronization therapy in women: US Food and Drug Administration meta-analysis of patientlevel data. Published online
More informationSupplementary Online Content
Supplementary Online Content Ebbing M, Bønaa KH, Nygård O, et al. Cancer incidence and mortality after treatment with folic acid and vitamin B 1. JAMA. 9;3(19):119-1. etable 1. Circulating Levels of B
More informationcloglog link function to transform the (population) hazard probability into a continuous
Supplementary material. Discrete time event history analysis Hazard model details. In our discrete time event history analysis, we used the asymmetric cloglog link function to transform the (population)
More informationCumulative metformin use and its impact on survival in gastric cancer patients after INDEX
Supplementary Data Cumulative metformin use and its impact on survival in gastric cancer patients after gastrectomy Lee et al. INDEX Supplementary Figure 1. Survival analysis according to stage : DM versus
More informationStatistical Methods for the Evaluation of Treatment Effectiveness in the Presence of Competing Risks
Statistical Methods for the Evaluation of Treatment Effectiveness in the Presence of Competing Risks Ravi Varadhan Assistant Professor (On Behalf of the Johns Hopkins DEcIDE Center) Center on Aging and
More informationTWISTED SURVIVAL: IDENTIFYING SURROGATE ENDPOINTS FOR MORTALITY USING QTWIST AND CONDITIONAL DISEASE FREE SURVIVAL. Beth A.
TWISTED SURVIVAL: IDENTIFYING SURROGATE ENDPOINTS FOR MORTALITY USING QTWIST AND CONDITIONAL DISEASE FREE SURVIVAL by Beth A. Zamboni BS Statistics, University of Pittsburgh, 1997 MS Biostatistics, Harvard
More informationEvaluating the Predictors of Chronic Kidney Disease Identification Number 8806 Biostatistics 699 Project
Evaluating the Predictors of Chronic Kidney Disease Identification Number 8806 Biostatistics 699 Project 1 01.29.2008 Appendix A contains supplemental results Appendix B contains analysis code Abstract:
More informationPackage Actigraphy. R topics documented: January 15, Type Package Title Actigraphy Data Analysis Version 1.3.
Type Package Title Actigraphy Data Analysis Version 1.3.2 Date 2016-01-14 Package Actigraphy January 15, 2016 Author William Shannon, Tao Li, Hong Xian, Jia Wang, Elena Deych, Carlos Gonzalez Maintainer
More informationStatistical Models for Censored Point Processes with Cure Rates
Statistical Models for Censored Point Processes with Cure Rates Jennifer Rogers MSD Seminar 2 November 2011 Outline Background and MESS Epilepsy MESS Exploratory Analysis Summary Statistics and Kaplan-Meier
More informationPackage wally. May 25, Type Package
Type Package Package wally May 25, 2017 Title The Wally Calibration Plot for Risk Prediction Models Version 1.0.9 Date 2017-04-28 Author Paul F Blanche , Thomas A. Gerds
More informationCommon Misunderstandings of Survival Time Analysis
Common isunderstandings of Survival Time Analysis ilensu Shanyinde Centre for Statistics in edicine University of Oxford 2 nd April 2012 Outline Introduction Essential features of the Kaplan-eier survival
More informationR/Bioconductor Center for Genomic Sciences Universidad Nacional Autónoma de México
R/Bioconductor Center for Genomic Sciences Universidad Nacional Autónoma de México Daniela Azucena García Soriano, dgarcia@lcg.unam.mx Yuvia Alhelí Pérez Rico, yperez@lcg.unam.mx October 23, 2009 Abstract
More informationSurvival analysis beyond the Cox-model
Survival analysis beyond the Cox-model Hans C. van Houwelingen Department of Medical Statistics Leiden University Medical Center The Netherlands jcvanhouwelingen@lumc.nl http://www.medstat.medfac.leidenuniv.nl/ms/hh/
More informationThe Statistical Analysis of Failure Time Data
The Statistical Analysis of Failure Time Data Second Edition JOHN D. KALBFLEISCH ROSS L. PRENTICE iwiley- 'INTERSCIENCE A JOHN WILEY & SONS, INC., PUBLICATION Contents Preface xi 1. Introduction 1 1.1
More informationA Handbook of Statistical Analyses Using R. Brian S. Everitt and Torsten Hothorn
A Handbook of Statistical Analyses Using R Brian S. Everitt and Torsten Hothorn CHAPTER 11 Analysing Longitudinal Data II Generalised Estimation Equations: Treating Respiratory Illness and Epileptic Seizures
More informationEthnic Disparities in the Treatment of Stage I Non-small Cell Lung Cancer. Juan P. Wisnivesky, MD, MPH, Thomas McGinn, MD, MPH, Claudia Henschke, PhD,
Ethnic Disparities in the Treatment of Stage I Non-small Cell Lung Cancer Juan P. Wisnivesky, MD, MPH, Thomas McGinn, MD, MPH, Claudia Henschke, PhD, MD, Paul Hebert, PhD, Michael C. Iannuzzi, MD, and
More informationCHL 5225 H Advanced Statistical Methods for Clinical Trials. CHL 5225 H The Language of Clinical Trials
CHL 5225 H Advanced Statistical Methods for Clinical Trials Two sources for course material 1. Electronic blackboard required readings 2. www.andywillan.com/chl5225h code of conduct course outline schedule
More informationSYNOPSIS. ER OROS Paliperidone: Clinical Study Report R SCH-301
SYNOPSIS Protocol No.: R076477-SCH-301 Title of Study: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study With an Open-Label Extension Evaluating Extended Release OROS Paliperidone in
More informationSupplementary. properties of. network types. randomly sampled. subsets (75%
Supplementary Information Gene co-expression network analysis reveals common system-level prognostic genes across cancer types properties of Supplementary Figure 1 The robustness and overlap of prognostic
More informationMethods for adjusting survival estimates in the presence of treatment crossover a simulation study
Methods for adjusting survival estimates in the presence of treatment crossover a simulation study Nicholas Latimer, University of Sheffield Collaborators: Paul Lambert, Keith Abrams, Michael Crowther
More informationSupplement for: CD4 cell dynamics in untreated HIV-1 infection: overall rates, and effects of age, viral load, gender and calendar time.
Supplement for: CD4 cell dynamics in untreated HIV-1 infection: overall rates, and effects of age, viral load, gender and calendar time. Anne Cori* 1, Michael Pickles* 1, Ard van Sighem 2, Luuk Gras 2,
More informationFrom Biostatistics Using JMP: A Practical Guide. Full book available for purchase here. Chapter 1: Introduction... 1
From Biostatistics Using JMP: A Practical Guide. Full book available for purchase here. Contents Dedication... iii Acknowledgments... xi About This Book... xiii About the Author... xvii Chapter 1: Introduction...
More informationSix Sigma Glossary Lean 6 Society
Six Sigma Glossary Lean 6 Society ABSCISSA ACCEPTANCE REGION ALPHA RISK ALTERNATIVE HYPOTHESIS ASSIGNABLE CAUSE ASSIGNABLE VARIATIONS The horizontal axis of a graph The region of values for which the null
More informationPackage mediation. September 18, 2009
Version 2.1 Date 2009-09-14 Title R Package for Causal Mediation Analysis Package mediation September 18, 2009 Author Luke Keele , Dustin Tingley , Teppei
More informationDevelopment and Validation of a Clinical Decision Score to Maximize Benefit and Minimize Harm from Intensive Blood Pressure Treatment
Development and Validation of a Clinical Decision Score to Maximize Benefit and Minimize Harm from Intensive Blood Pressure Treatment Sanjay Basu, MD, PhD basus@stanford.edu Disclosures and conflicts of
More informationEstimating and comparing cancer progression risks under varying surveillance protocols: moving beyond the Tower of Babel
Estimating and comparing cancer progression risks under varying surveillance protocols: moving beyond the Tower of Babel Jane Lange March 22, 2017 1 Acknowledgements Many thanks to the multiple project
More informationEvaluation of AJCC, UICC, and Brigham and Women's Hospital Tumor Staging for Cutaneous Squamous Cell Carcinoma
Evaluation of AJCC, UICC, and Brigham and Women's Hospital Tumor Staging for Cutaneous Squamous Cell Carcinoma Karia, et al Methods Details of data collectionfeatures of primary tumors including anatomic
More informationName: BIOS 703 MIDTERM EXAMINATIONS (5 marks per question, total = 100 marks)
Name: BIOS 703 MIDTERM EXAMINATIONS (5 marks per question, total = 100 marks) You will have 75 minutest to complete this examination. Some of the questions refer to Crizotinib in ROS1- Rearranged Non Small-
More informationIntroduction to Meta-analysis of Accuracy Data
Introduction to Meta-analysis of Accuracy Data Hans Reitsma MD, PhD Dept. of Clinical Epidemiology, Biostatistics & Bioinformatics Academic Medical Center - Amsterdam Continental European Support Unit
More informationNational Lung Screening Trial Results
National Lung Screening Trial Results Ella A. Kazerooni, M.D. Professor & Director Cardiothoracic Radiology Associate Chair for Clinical Affairs University of Michigan NLST STOPPED! Lung cancer trial results
More informationData Exploration and Visualization
Data Exploration and Visualization Bu eğitim sunumları İstanbul Kalkınma Ajansı nın 2016 yılı Yenilikçi ve Yaratıcı İstanbul Mali Destek Programı kapsamında yürütülmekte olan TR10/16/YNY/0036 no lu İstanbul
More informationDevelopment and validation of QDiabetes-2018 risk prediction algorithm to estimate future risk of type 2 diabetes: cohort study
Development and validation of QDiabetes-2018 risk prediction algorithm to estimate future risk of type 2 diabetes: cohort study Julia Hippisley-Cox, 1,2 Carol Coupland 1 1 Division of Primary Care, University
More informationSupplementary Online Content
Supplementary Online Content Jänne PA, van den Heuvel MM, Barlesi F, et al. Effect of selumetinib plus docetaxel compared with docetaxel alone and progression-free survival in patients with KRASmutant
More informationOverview. All-cause mortality for males with colon cancer and Finnish population. Relative survival
An overview and some recent advances in statistical methods for population-based cancer survival analysis: relative survival, cure models, and flexible parametric models Paul W Dickman 1 Paul C Lambert
More informationComputer Age Statistical Inference. Algorithms, Evidence, and Data Science. BRADLEY EFRON Stanford University, California
Computer Age Statistical Inference Algorithms, Evidence, and Data Science BRADLEY EFRON Stanford University, California TREVOR HASTIE Stanford University, California ggf CAMBRIDGE UNIVERSITY PRESS Preface
More informationOrganizing Data. Types of Distributions. Uniform distribution All ranges or categories have nearly the same value a.k.a. rectangular distribution
Organizing Data Frequency How many of the data are in a category or range Just count up how many there are Notation x = number in one category n = total number in sample (all categories combined) Relative
More informationModelling the recurrence of bladder cancer
Modelling the recurrence of bladder cancer Gregorio Rubio 1, Cristina Santamaría 1, Belén García 1, and José Luis Pontones 2 1 Matemática multidisciplinar Universidad Politécnica Valencia (Spain) (e-mail:
More information4. STATA output of the analysis
Biostatistics(1.55) 1. Objective: analyzing epileptic seizures data using GEE marginal model in STATA.. Scientific question: Determine whether the treatment reduces the rate of epileptic seizures. 3. Dataset:
More informationThe role of cytoreductive. nephrectomy in elderly patients. with metastatic renal cell. carcinoma in an era of targeted. therapy
The role of cytoreductive nephrectomy in elderly patients with metastatic renal cell carcinoma in an era of targeted therapy Dipesh Uprety, MD Amir Bista, MD Yazhini Vallatharasu, MD Angela Smith, MA David
More informationAn Overview of Survival Statistics in SEER*Stat
An Overview of Survival Statistics in SEER*Stat National Cancer Institute SEER Program SEER s mission is to provide information on cancer statistics in an effort to reduce the burden of cancer among the
More informationApplication of Artificial Neural Network-Based Survival Analysis on Two Breast Cancer Datasets
Application of Artificial Neural Network-Based Survival Analysis on Two Breast Cancer Datasets Chih-Lin Chi a, W. Nick Street b, William H. Wolberg c a Health Informatics Program, University of Iowa b
More informationThe rmeta Package February 17, 2001
R topics documented: The rmeta Package February 17, 2001 catheter......................................... 1 funnelplot........................................ 2 meta.dsl........................................
More informationThe results of the clinical exam first have to be turned into a numeric variable.
Worked examples of decision curve analysis using Stata Basic set up This example assumes that the user has installed the decision curve ado file and has saved the example data sets. use dca_example_dataset1.dta,
More informationEMA Pediatric Web Synopsis Protocol A November 2011 Final PFIZER INC.
PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. For publications based on this study, see associated bibliography.
More informationSupplementary Materials
Supplementary Materials Supplementary figure 1. Taxonomic representation summarized at genus level. Fecal microbiota from a separate set of Jackson and Harlan mice prior to irradiation. A taxon was included
More informationIntroduction At times when pollen is scarce in the natural environment
Artificial Bee Diets Taryn Major Linda Eaton Kathy Haskard Philip Vlaskovsky Rob Manning (Department of Agriculture and Food) Introduction At times when pollen is scarce in the natural environment Bees
More informationReadings: Textbook readings: OpenStax - Chapters 1 11 Online readings: Appendix D, E & F Plous Chapters 10, 11, 12 and 14
Readings: Textbook readings: OpenStax - Chapters 1 11 Online readings: Appendix D, E & F Plous Chapters 10, 11, 12 and 14 Still important ideas Contrast the measurement of observable actions (and/or characteristics)
More informationSupplemental Table 1: NHLBI Transplant Protocols
Supplemental Table 1: NHLBI Transplant Protocols N.B: Second column ( n ) lists number of patients for whom pre-sct samples could be identified. In addition to above, two protocols enrolled a single patient
More informationImpact of Screening Colonoscopy on Outcomes in Colon Cancer Surgery
Impact of Screening Colonoscopy on Outcomes in Colon Cancer Surgery The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters. Citation
More informationApplication of Cox Regression in Modeling Survival Rate of Drug Abuse
American Journal of Theoretical and Applied Statistics 2018; 7(1): 1-7 http://www.sciencepublishinggroup.com/j/ajtas doi: 10.11648/j.ajtas.20180701.11 ISSN: 2326-8999 (Print); ISSN: 2326-9006 (Online)
More information17/10/2012. Could a persistent cough be whooping cough? Epidemiology and Statistics Module Lecture 3. Sandra Eldridge
Could a persistent be whooping? Epidemiology and Statistics Module Lecture 3 Sandra Eldridge Aims of lecture To explain how to interpret a confidence interval To explain the different ways of comparing
More informationA Study on Type 2 Diabetes Mellitus Patients Using Regression Model and Survival Analysis Techniques
Available online at www.ijpab.com Shaik et al Int. J. Pure App. Biosci. 6 (1): 514-522 (2018) ISSN: 2320 7051 DOI: http://dx.doi.org/10.18782/2320-7051.5999 ISSN: 2320 7051 Int. J. Pure App. Biosci. 6
More informationStatistics and Epidemiology Practice Questions
1. Which of the following is not considered a measure of central tendency? a. Median b. Range c. Mode d. Average 2. Given the following set of values, what is the median? 4 5 9 3 8 3 7 1 5 3 a. 3 b. 5
More informationBRaf V600E cooperates with Pten silencing to elicit metastatic melanoma (Nature Genetics Supplementary Information)
BRaf V600E cooperates with Pten silencing to elicit metastatic melanoma (Nature Genetics Supplementary Information) David Dankort, David P. Curley, Robert A. Cartlidge, Betsy Nelson, Anthony N. Karnezis,
More information# Assessment of gene expression levels between several cell group types is a common application of the unsupervised technique.
# Aleksey Morozov # Microarray Data Analysis Using Hierarchical Clustering. # The "unsupervised learning" approach deals with data that has the features X1,X2...Xp, but does not have an associated response
More informationPackage p3state.msm. R topics documented: February 20, 2015
Package p3state.msm February 20, 2015 Type Package Depends R (>= 2.8.1),survival,base Title Analyzing survival data Version 1.3 Date 2012-06-03 Author Luis Meira-Machado and Javier Roca-Pardinas
More informationUsing the Palliative Performance Scale to Provide Meaningful Survival Estimates
134 Journal of Pain and Symptom Management Vol. 38 No. 1 July 2009 Original Article Using the Palliative Performance Scale to Provide Meaningful Survival Estimates Francis Lau, PhD, Michael Downing, MD,
More informationIDENTIFYING STAGE 1 HEPATOCELLULAR CARCINOMA PATIENTS WITH POOR PROGNOSIS
IDENTIFYING STAGE 1 HEPATOCELLULAR CARCINOMA PATIENTS WITH POOR PROGNOSIS J. B. NATION Abstract. Aim: The purpose of this note is to show that survival times for stage 1 HCC patients has a bimodal distribution,
More informationHour 2: lm (regression), plot (scatterplots), cooks.distance and resid (diagnostics) Stat 302, Winter 2016 SFU, Week 3, Hour 1, Page 1
Agenda for Week 3, Hr 1 (Tuesday, Jan 19) Hour 1: - Installing R and inputting data. - Different tools for R: Notepad++ and RStudio. - Basic commands:?,??, mean(), sd(), t.test(), lm(), plot() - t.test()
More informationChapter 2 Psychological Research, Methods and Statistics
Chapter 2 Psychological Research, Methods and Statistics Section 1- What is Research? Psychologists must first decide how to approach the research issue. Then psychologists conduct the research in one
More informationStatistical Challenges in Immunotherapy: Non Proportional Hazard Model. BBS / PSI CIT event 15-June-2017, Basel Claude BERGE, Roche
Statistical Challenges in Immunotherapy: Non Proportional Hazard Model BBS / PSI CIT event 15-June-2017, Basel Claude BERGE, Roche 1 Statistical Challenges Biomarker Efficacy Endpoint Study Design & Analysis
More informationAPPENDIX N. Summary Statistics: The "Big 5" Statistical Tools for School Counselors
APPENDIX N Summary Statistics: The "Big 5" Statistical Tools for School Counselors This appendix describes five basic statistical tools school counselors may use in conducting results based evaluation.
More informationPart [1.0] Introduction to Development and Evaluation of Dynamic Predictions
Part [1.0] Introduction to Development and Evaluation of Dynamic Predictions A Bansal & PJ Heagerty Department of Biostatistics University of Washington 1 Biomarkers The Instructor(s) Patrick Heagerty
More informationCase Studies in Bayesian Augmented Control Design. Nathan Enas Ji Lin Eli Lilly and Company
Case Studies in Bayesian Augmented Control Design Nathan Enas Ji Lin Eli Lilly and Company Outline Drivers for innovation in Phase II designs Case Study #1 Pancreatic cancer Study design Analysis Learning
More informationArbolishvili GN, Mareev VY Institute of Clinical Cardiology, Moscow, Russia
THE VALUE OF 24 H HEART RATE VARIABILITY IN PREDICTING THE MODE OF DEATH IN PATIENTS WITH HEART FAILURE AND SYSTOLIC DYSFUNCTION IN BETA-BLOCKING BLOCKING ERA Arbolishvili GN, Mareev VY Institute of Clinical
More informationCancer Treatment by Alternating Electric Fields (TTFields); Physical Basis & Clinical Trial Results. Madrid, March 2015
1 Cancer Treatment by Alternating Electric Fields (TTFields); Physical Basis & Clinical Trial Results Madrid, March 2015 2 Cancer Treatments Surgical - whenever possible, Effective mostly in Early stages,
More informationUNIT V: Analysis of Non-numerical and Numerical Data SWK 330 Kimberly Baker-Abrams. In qualitative research: Grounded Theory
UNIT V: Analysis of Non-numerical and Numerical Data SWK 330 Kimberly Baker-Abrams In qualitative research: analysis is on going (occurs as data is gathered) must be careful not to draw conclusions before
More informationDISCLOSURE SLIDE. ARGOS: research funding, scientific advisory board
INTERIM ANALYSIS OF THE PHASE 3 ADAPT TRIAL EVALUATING ROCAPULDENCEL-T (AGS-003), AN INDIVIDUALIZED IMMUNOTHERAPY FOR THE TREATMENT OF NEWLY-DIAGNOSED PATIENTS WITH METASTATIC RENAL CELL CARCINOMA (MRCC)
More informationLOGO. Statistical Modeling of Breast and Lung Cancers. Cancer Research Team. Department of Mathematics and Statistics University of South Florida
LOGO Statistical Modeling of Breast and Lung Cancers Cancer Research Team Department of Mathematics and Statistics University of South Florida 1 LOGO 2 Outline Nonparametric and parametric analysis of
More informationMaking Inferences from Experiments
11.6 Making Inferences from Experiments Essential Question How can you test a hypothesis about an experiment? Resampling Data Yield (kilograms) Control Group Treatment Group 1. 1.1 1.2 1. 1.5 1.4.9 1.2
More informationLocoregional treatment Session Oral Abstract Presentation Saulo Brito Silva
Locoregional treatment Session Oral Abstract Presentation Saulo Brito Silva Background Post-operative radiotherapy (PORT) improves disease free and overall suvivallin selected patients with breast cancer
More informationRimegepant Pivotal Phase 3 Trial Results - Conference Call March 26, Biohaven
Rimegepant Pivotal Phase 3 Trial Results - Conference Call March 26, 2018 1 Forward-Looking Statement This presentation contains forward-looking statements, including: statements about our plans to develop
More informationChapter 1: Data Collection Pearson Prentice Hall. All rights reserved
Chapter 1: Data Collection 2010 Pearson Prentice Hall. All rights reserved 1-1 Statistics is the science of collecting, organizing, summarizing, and analyzing information to draw conclusions or answer
More informationDevelopment of restricted mean survival time difference in network metaanalysis based on data from MACNPC update.
Development of restricted mean survival time difference in network metaanalysis based on data from MACNPC update. Claire Petit, Pierre Blanchard, Jean-Pierre Pignon, Béranger Lueza June 2017 CONTENTS Context...
More informationContent. Basic Statistics and Data Analysis for Health Researchers from Foreign Countries. Research question. Example Newly diagnosed Type 2 Diabetes
Content Quantifying association between continuous variables. Basic Statistics and Data Analysis for Health Researchers from Foreign Countries Volkert Siersma siersma@sund.ku.dk The Research Unit for General
More informationDescribe what is meant by a placebo Contrast the double-blind procedure with the single-blind procedure Review the structure for organizing a memo
Please note the page numbers listed for the Lind book may vary by a page or two depending on which version of the textbook you have. Readings: Lind 1 11 (with emphasis on chapters 10, 11) Please note chapter
More informationImpaired Chronotropic Response to Exercise Stress Testing in Patients with Diabetes Predicts Future Cardiovascular Events
Diabetes Care Publish Ahead of Print, published online May 28, 2008 Chronotropic response in patients with diabetes Impaired Chronotropic Response to Exercise Stress Testing in Patients with Diabetes Predicts
More informationMethodology for Statistical Analysis of
Environmental Health Perspectives Vol. 68, pp. 5-9, 1986 Methodology for Statistical Analysis of SENCAR Mouse Skin Assay Data by Judy A. Stober* Various response measures and statistical methods appropriate
More informationSection 3: Economic evaluation
Section 3: Economic evaluation PERSPECTIVES OF AN EVALUATOR DR BONNY PARKINSON SENIOR RESEARCH FELLOW MACQUARIE UNIVERSITY CENTRE FOR THE HEALTH ECONOMY (MUCHE) Disclaimer The views presented are my own
More informationOverview. Goals of Interpretation. Methodology. Reasons to Read and Evaluate
Overview Critical Literature Evaluation and Biostatistics Ahl Ashley N. Lewis, PharmD, BCPS Clinical Specialist, Drug Information UNC Hospitals Background Review of basic statistics Statistical tests Clinical
More informationSYNOPSIS A two-stage randomized, open-label, parallel group, phase III, multicenter, 7-month study to assess the efficacy and safety of SYMBICORT
Drug product: Drug substance(s): Edition No.: Study code: SYMBICORT pmdi 160/4.5 g Budesonide/formoterol D5896C00005 Date: 8 May 2006 SYNOPSIS A two-stage randomized, open-label, parallel group, phase
More informationStill important ideas
Readings: OpenStax - Chapters 1 11 + 13 & Appendix D & E (online) Plous - Chapters 2, 3, and 4 Chapter 2: Cognitive Dissonance, Chapter 3: Memory and Hindsight Bias, Chapter 4: Context Dependence Still
More informationIndividual Study Table Referring to Part of Dossier: Volume: Page:
Synopsis Abbott Laboratories Name of Study Drug: Paricalcitol Capsules (ABT-358) (Zemplar ) Name of Active Ingredient: Paricalcitol Individual Study Table Referring to Part of Dossier: Volume: Page: (For
More informationAdvanced Decision Analysis: Markov Models
Advanced Decision Analysis: Markov Models Reasons to understand Markov models It s the standard in academia Very powerful/flexible tool simple decision trees relatively inflexible limited time frame hard
More informationPRINCIPLES OF STATISTICS
PRINCIPLES OF STATISTICS STA-201-TE This TECEP is an introduction to descriptive and inferential statistics. Topics include: measures of central tendency, variability, correlation, regression, hypothesis
More informationImmunotherapy in the Adjuvant Setting for Melanoma: What You Need to Know
Immunotherapy in the Adjuvant Setting for Melanoma: What You Need to Know Jeffrey Weber, MD, PhD Laura and Isaac Perlmutter Cancer Center NYU Langone Medical Center New York, New York What Is the Current
More informationDiagnostic methods 2: receiver operating characteristic (ROC) curves
abc of epidemiology http://www.kidney-international.org & 29 International Society of Nephrology Diagnostic methods 2: receiver operating characteristic (ROC) curves Giovanni Tripepi 1, Kitty J. Jager
More informationComprehensive Research Plan: Inhaled corticosteroids + long-acting beta agonists (ICS+LABA) for the treatment of asthma
Comprehensive Research Plan: Inhaled corticosteroids + long-acting beta agonists (ICS+LABA) for the treatment of asthma Pharmacoepidemiology Unit July 10, 2014 30 Bond Street, Toronto ON, M5B 1W8 www.odprn.ca
More informationA statistical evaluation of the effects of gender differences in assessment of acute inhalation toxicity
A statistical evaluation of the effects of gender differences in assessment of acute inhalation toxicity Human and Experimental Toxicology 30(3) 217 238 ª The Author(s) 2010 Reprints and permission: sagepub.co.uk/journalspermissions.nav
More informationAge-standardised Net Survival & Cohort and Period Net Survival Estimates
Cancer survival analysis using population-based data Granada, 27-28 March 2017 Age-standardised Net Survival & Cohort and Period Net Survival Estimates Cancer survival analysis using population-based data
More informationPERCUTANEOUS STRUCTURAL UPDATES TAVR WATCHMAN(LEFT ATRIAL APPENDAGE OCCLUDERS) MITRACLIP PARAVALVULAR LEAK REPAIRS ASD/PFO CLOSURES VALVULOPLASTIES
PERCUTANEOUS STRUCTURAL UPDATES TAVR WATCHMAN(LEFT ATRIAL APPENDAGE OCCLUDERS) MITRACLIP PARAVALVULAR LEAK REPAIRS ASD/PFO CLOSURES VALVULOPLASTIES Dr.Vinny K.Ram No disclosures TAVR 1 Lesson number 1:
More informationNivolumab Addendum to Commission A
IQWiG Reports Commission No. A15-58 Nivolumab Addendum to Commission A15-32 1 Addendum Commission:A15-58 Version: 1.0 Status: 13 January 2016 1 Translation of addendum A15-58 Nivolumab Addendum zum Auftrag
More informationNormal Distribution: Homework *
OpenStax-CNX module: m16978 1 Normal Distribution: Homework * Susan Dean Barbara Illowsky, Ph.D. This work is produced by OpenStax-CNX and licensed under the Creative Commons Attribution License 2.0 Exercise
More informationNature Genetics: doi: /ng Supplementary Figure 1. Details of sequencing analysis.
Supplementary Figure 1 Details of sequencing analysis. (a) Flow chart showing which patients fall into each category and were used for analysis. (b) Graph showing the average and median coverage for all
More informationBiostatistics. Donna Kritz-Silverstein, Ph.D. Professor Department of Family & Preventive Medicine University of California, San Diego
Biostatistics Donna Kritz-Silverstein, Ph.D. Professor Department of Family & Preventive Medicine University of California, San Diego (858) 534-1818 dsilverstein@ucsd.edu Introduction Overview of statistical
More informationAuthor's response to reviews
Author's response to reviews Title: Characteristic mtor activity in Hodgkin-lymphomas offers a potential therapeutic target in high risk disease - a combined tissue microarray, in vitro and in vivo study
More information